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Genetic testing of PKD1 and PKD2 is useful for the
diagnosis and prognosis of autosomal dominant poly-
cystic kidney disease; however, analysis is complicated
by the large transcript size, the complexity of the gene
region, and the high level of gene variations. We devel-
oped a novel mutation screening assay for PKD1 by
directly sequencing long-range (LR) PCR products. By
using this method, the entire PKD1 coding region was
amplified by nine reactions, generating product sizes
from 2 to 6 kb, circumventing the need for specific PCR
amplification of individual exons. This method was
compared with direct sequencing used by a reference
laboratory and the SURVEYOR-WAVE Nucleic Acid High
Sensitivity Fragment Analysis System (Transgenomic)
screeningmethod for five patients with autosomal dom-
inant polycystic kidney disease. A total of 53 heterozy-
gous genetic changes were identified by LR PCR se-
quencing, including 41 (of 42) variations detected by
SURVEYOR nuclease and all 32 variations reported by
the reference laboratory, detecting an additional 12 in-
tronic changes not identified by the other twomethods.
Compared with the reference laboratory, LR PCR se-
quencing had a sensitivity of 100%, a specificity of
98.5%, and an accuracy of 98.8%; compared with the
SURVEYOR-WAVE method, it had a sensitivity of 97.1%,
a specificity of 100%, and an accuracy of 99.4%. In con-
clusion, LR PCR sequencing was superior to the direct
sequencing and screening methods for detecting ge-
netic variations, achieving high sensitivity and im-
proved intronic coverage with a faster turnaround time
and lower costs, and providing a reliable tool for com-
plex genetic analyses. (J Mol Diagn 2012, 14:305-313;
http://dx.doi.org/10.1016/j.jmoldx.2012.02.007)Autosomal dominant polycystic kidney disease (AD-
PKD) is the most common inherited kidney disease,
affecting approximately 1 in 500 individuals in the
United States and 12.5 million patients worldwide. It is
characterized by bilateral kidney cyst development1–4
and progressive chronic kidney disease, leading to
end-stage renal disease.5,6 ADPKD is caused by mu-
tations in two genes, with the PKD1 gene accounting
for 75% to 85% of the cases and the PKD2 gene re-
sponsible for the remainder of the cases.7 Genetic
testing plays an increasingly significant role in the di-
agnosis of patients with an unclear renal phenotype,
particularly in the absence of a known family history,
and in the evaluation of family members who are con-
sidering kidney donation to affected individuals.8 How-
ever, genetic testing is complicated by the presence of
PKD1 homologous genes (HGs), the large size of
PKD1, and marked allelic heterogeneity of the disease-
associated mutations.9,10
The main strategies used for ADPKD genetic analysis
are all PCR based, followed by sequencing of the corre-
sponding exons. Although the entire PKD2 gene and the
single-copy region of the PKD1 gene can be directly
amplified by PCR from genomic DNA, the duplicated
PKD1 region requires nested PCR to amplify the true
gene among the highly identical HGs.11 The nested-PCR
approach comprises two primary steps: a long-range
(LR) PCR with primers located in the rare mismatch sites
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Fragment
Size
(bp) Exon Forward primer Reverse primer
Temperature
(°C)
Gene1 2278 1 5=-CGCAGCCTTACCATCCACCT-3= 5=-TCATCGCCCCTTCCTAAGCA-3= 64
Gene2-7 4041 2-7 5=-CCCCGAGTAGCTGGAACTACAGTTAC-
ACACT-3=
5=-CGTCCTGCTGTGCCAGAGGCG-3= 70
Gene8-12 3893 8-12 5=-ACGTCTGCGAGCTGCAGCCC-3= 5=-CTGCAGGGACAGGCGTCAGTGA-3= 70
Gene13-15 4391 13-15 5=-TGGAGGGAGGGACGCCAATC-3= 5=-GTCAACGTGGGCCTCCAAGT-3= 65
Gene15-21 5253 15-21 5=-ATCCCTGGGGGTCCTACCATCTCTTA-3= 5=-ACACAGGACAGAACGGCTGAGGCTA-3= 68
Gene22-26 3276 22-26 5=-ATGCTTAGTGAGGAGGCTGTGGG-
GGTCCA-3=
5=-GCTTAAAGGGGAATGGCTTAAACCCG-3= 70
Gene27-34 3916 27-34 5=-CGGGTCACCGGTTGTGGCA-3= 5=-ATGAGGCTCTTTCCACAGACAAC-
AGAGGTT-3=
70
Gene35-41 2632 35-41 5=-CAAGAGGCTCAAGAAACTGCCCG-3= 5=-GGGCTGTGGAAGCCGCCTA-3= 68
Gene42-46 2370 42-46 5=-GAGTAGTTCTCCAGGAGTGCCG-3= 5=-ATTCTGCCTGGCCCTCGGCCTT-3= 63Table 2. LR PCR Amplification Conditions
PKD1 sequence PCR conditions
Gene1 99°C for 5 minutes; followed by cooling down to 95°C for 2 minutes; and 35 cycles of
95°C for 1 minute, 62°C for 1 minute, and 72°C for 3 minutes, with a final extension
step at 72°C for 10 minutes
Gene2-7 and Gene8-12 Touchdown protocol composed of an initial step of 95°C for 3 minutes; followed by 14
cycles of 95°C for 30 seconds, 74°C for 30 seconds, with a decrease of 0.5°C per
cycle, and 68°C for 5 minutes; followed by 30 cycles of 95°C for 30 seconds, 67°C for
30 seconds, and 68°C for 5 minutes, with a final extension step of 72°C for 10 minutes
Gene13-15 95°C for 3.15 minutes, followed by 35 cycles of 95°C for 20 seconds and 68°C for 5
minutes, with a final extension step at 72°C for 7 minutes
Gene15-21 95°C for 3 minutes, followed by 35 cycles of 95°C for 30 seconds and 68°C for 4.5
minutes, with a final extension step at 72°C for 10 minutes
Gene22-26, Gene27-34,
Gene35-41, and
Gene42-46
94°C for 3 minutes; followed by 14 cycles of 94°C for 30 seconds, 66°C for 30 seconds,
with a decrease of 0.5°C per cycle, and 68°C for 3.5 minutes; followed by 30 cycles
of 95°C for 30 seconds, 59°C for 30 seconds, and 68°C for 3.5 minutes, with a final
extension step of 72°C for 10 minutesTable 3. PKD1 Sequencing Primers
Primer name Sequence
Genomic position
(of 5= first bp)
Distance to exon-
intron junction
Exons
covered
PKD1–exon1-F 5=-GCGTCGCTCAGCAGCAGGT-3= 2,185,830 140 Ex1 1
PKD1–exon1-R 5=-GCCCGCGTCCTGCTTCCC-3= 2,185,383 93 Ex1
PKD1–exon2-3-F 5=-GGGATGCTGGCAATGTGTGGGAT-3= 2,169,468 89 Ex2 2-3
PKD1–exon2-3-R 5=-GGACCAACTGGGAGGGCAGAA-3= 2,169,038 77 Ex3
PKD1–exon4-F 5=-GGCGGTGCTGTCAGGGTG-3= 2,168,948 102 Ex4 4
PKD1–exon4-R 5=-CCAGAGAGGCCTTCCTGAGC-3= 2,168,582 95 Ex4
PKD1–exon5A-F 5=-GAACAGCATGGGAGCCTGTGAGT-3= 2,168,561 98 Ex5 5
PKD1–exon5A-R 5=-AGCCGGCCCAGCGGCATC-3= 2,168,033 Within an exon
PKD1–exon5B-F 5=-GCCTGTCCCTCTGCTCCG-3= 2,168,262 Within an exon 5
PKD1–exon5B-R 5=-GTGTCAACGGTCAGTGTGGGC-3= 2,167,696 96 Ex5
PKD1–exon6-F 5=-GTGTCTGCTGCCCACTCCC-3= 2,167,787 124 Ex6 6
PKD1–exon6-R 5=-CTCCTTCCTCCTGAGACTCCC-3= 2,167,397 93 Ex6
PKD1–exon7-F 5=-GCTGCTGTGAGGGTGGGAGGA-3= 2,167,120 66 Ex7 7
PKD1–exon7-R 5=-TCCACCGCGGGCGCTCGGCA-3= 2,166,763 71 Ex7
PKD1–exon8-F 5=-CTGGGCTGAGGAGGAGGG-3= 2,166,760 115 Ex8 8
PKD1–exon8-R 5=-GGGCACAAGCAACATTAAGGCCC-3= 2,166,413 117 Ex8
PKD1–exon9-F 5=-CCTCTTCCTGGGAAGTTCGGGT-3= 2,166,206 87 Ex9 9
PKD1–exon9-R 5=-ACTCTGGTGGCCACAGGACCA-3= 2,165,895 98 Ex9
PKD1–exon10-F 5=-GCAGGCAGTTGGGCATCTCTG-3= 2,165,697 71 Ex10 10
PKD1–exon10-R 5=-GACCCTGGGCAGCAGACAG-3= 2,165,309 70 Ex10
PKD1–exon11A-F 5=-GTGTGGCTGACGAAGCGGG-3= 2,165,035 109 Ex11 11
PKD1–exon11A-R 5=-CCGTGGCGTTGGCACCAG-3= 2,164,455 Within an exon
PKD1–exon11B-F 5=-CGCTATGAGGTCCGGGCAG-3= 2,164,641 Within an exon 11
PKD1–exon11B-R 5=-CCCTCACTGGGAAGCCAGG-3= 2,164,077 93 Ex11
PKD1–exon12-F 5=-GGACTCTCCAGCCCGACG-3= 2,163,387 94 Ex12 12
PKD1–exon12-R 5=-GCAGAGGTGAAGGTGGAGC-3= 2,163,088 74 Ex12
PKD1–exon13-14-F 5=-GTGGAGGGAGGGACGCCAA-3= 2,163,037 73 Ex13 13-14
PKD1–exon13-14-R 5=-GTCACAGTGAGGGCTGTTGGG-3= 2,162,230 111 Ex14
PKD1–exon15A-F 5=-TTCTGCCGAGCGGGTGGG-3= 2,161,938 64 Ex15 15
PKD1–exon15A-R 5=-CATGTCGAAGGTCCACGTGATGT-3= 2,161,427 Within an exontable continues
uman r
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amplify each individual exon. This step prevents amplifi-
cation of the PKD1 HGs that potentially could confound
Table 3. Continued
Primer name Sequence
PKD1–exon15B-F 5=-GACATGAGCCTGGCCGTGG-3=
PKD1–exon15B-R 5=-CCACCTCTGGCTCCACGCA-3=
PKD1–exon15C-F 5=-CACGCGGAGCGGCACGTT-3=
PKD1–exon15C-R 5=-GGTGACCTCCGGACCCTC-3=
PKD1–exon15D-F 5=-TCTGCTGTGGGCCGTGGG-3=
PKD1–exon15D-R 5=-CTGTACCGTGTGGTTGGTGGG-3=
PKD1–exon15E-F 5=-ACAGCATCTTCGTCTATGTCCTG-
PKD1–exon15E-R 5=-GGTTCCCTGCCGTCATGGTG-3=
PKD1–exon15F-F 5=-GGGCTGAGCTGGGAGACCT-3=
PKD1–exon15F-R 5=-GACAGCTGAGCCGGCAGC-3=
PKD1–exon15G-F 5=-CTGTGGGCCAGCAGCAAGGT-3=
PKD1–exon15G-R 5=-CGTGCGGTTCTCACTGCCCA-3=
PKD1–exon15H-F 5=-GACGTCACCTACACGCCCG-3=
PKD1–exon15H-R 5=-CCTCCCAGCGGTACTCAGTCT-3=
PKD1–exon15I-F 5=-GATGCGGCGATCACAGCGCA-3=
PKD1–exon15I-R 5=-GGCCAGCCCTGGTGGCAA-3=
PKD1–exon16-F 5=-GGCCCGTCCTCAGTGCCT-3=
PKD1–exon16-R 5=-GCGGCCTCCACCAGCACTA-3=
PKD1–exon17-18-F 5=-GAAACCTGGAGTTTGGGAGCAGC-
PKD1–exon17-18-R 5=-TGACGTCACAGAGTCGGG-3=
PKD1–exon19-20-F 5=-GCACGGGTGAGTGCAGGC-3=
PKD1–exon19-20-R 5=-CCGGGATGAGCCCTCTGCAA-3=
PKD1–exon21-F 5=-AGTCGTGGGCATCTGCTGGC-3=
PKD1–exon21-R 5=-CAAGCTGCCCGTCTGCCCT-3=
PKD1–exon22-F 5=-CAGGTGAGGACCCGTGTAGAGA-3
PKD1–exon22-R 5=-GGGAGGAGGGAGGCAGAG-3=
PKD1–exon23A-F 5=-GCACCTCGCTCTCTGCCC-3=
PKD1–exon23A-R 5=-GCCACCTTGGTGGAGACGG-3=
PKD1–exon23B-F 5=-GGCTGCCACTTCTCCATCCC-3=
PKD1–exon23B-R 5=-GACACCCATGGAAGCCCTACG-3=
PKD1–exon24-F 5=-CGTGGCAGAGGGTGGGCT-3=
PKD1–exon24-R 5=-CTCGCTGCCTGCCGTCCC-3=
PKD1–exon25-26-F 5=-GGCTCTGAGACTGCGACATCCAA-
PKD1–exon25-26-R 5=-CTTGTTCTGACGCCTGCGACG-3=
PKD1–exon27-28-F 5=-GCTGAGATGACTTGCCTGGGATG-
PKD1–exon27-28-R 5=-ACTGCAGGAGGCCACGGG-3=
PKD1–exon29-30-F 5=-CTCCGTGGGAGGTTGGGCA-3=
PKD1–exon29-30-R 5=-CGCCTTTCCCTCTGGCTGC-3=
PKD1–exon31-32F 5=-CGGGCTCTGTCCTGTCTGC-3=
PKD1–exon31-32R 5=-CCCAGCAAGGACACGCAGC-3=
PKD1–exon33-34-F 5=-GGAAGCCCAGGGTGTCCGT-3=
PKD1–exon33-34-R 5=-CAGCCCTGCCCTGGCACC-3=
PKD1–exon35-F 5=-CAAGAGGCTCAAGAAACTGCCCG-
PKD1–exon36-R 5=-GAGAAGTACAGGGCTTCCAGCAA-
PKD1–exon37-F 5=-CTCGGCTGGGAGCCACTG-3=
PKD1–exon37-R 5=-GCCTTCTGAGGTGAGGAAAGGG-3
PKD1–exon38-F 5=-CCACACCTGCCGCAGCCAT-3=
PKD1–exon38-R 5=-CAAAGGTATCTACACATGTCCAC-
PKD1–exon39-F 5=-GCCAGCAGGGCAGTGGGA-3=
PKD1–exon39-R 5=-CAGCTAGGGAGCAGGGCTGA-3=
PKD1–exon40-F 5=-GTGGCGCCGAACCAGAGC-3=
PKD1–exon41-R 5=-GGGCTGTGGAAGCCGCCTA-3=
PKD1–exon42-F 5=-CCTCAGCCACGCCTGCACT-3=
PKD1–exon42-R 5=-GGGTGAGACGCTGCCGGG-3=
PKD1–exon43-F 5=-CAGCGTCCCTCCCGCCCT-3=
PKD1–exon44-R 5=-CAGGAAGACACGAGCTGCGG-3=
PKD1–exon45-F 5=-GCTGGCCATCCTGGTAGGTGA-3=
PKD1–exon45-R 5=-GGACTTTGTGGCGGAACTGGG-3=
PKD1–exon46-F 5=-GGAGAGGGACACGCCCTG-3=
PKD1–exon46-R 5=-ATTCTGCCTGGCCCTCGGCCTT-3
The genomic primer positions were according to the February 2009 h
Ex, exon.the analysis.11 However, this process is highly labor in-tensive, susceptible to PCR contamination, and expen-
sive. The number of sequencing reactions can be sub-
stantially reduced by mutation screening procedures12;
Genomic position
(of 5= first bp)
Distance to exon-
intron junction
Exons
covered
2,161,516 Within an exon 15
2,161,027 Within an exon
2,161,121 Within an exon 15
2,160,626 Within an exon
2,160,706 Within an exon 15
2,160,215 Within an exon
2,160,303 Within an exon 15
2,159,812 Within an exon
2,159,899 Within an exon 15
2,159,417 Within an exon
2,159,494 Within an exon 15
2,159,012 Within an exon
2,159,095 Within an exon 15
2,158,603 Within an exon
2,158,688 Within an exon 15
2,158,164 89 Ex15
2,158,167 134 Ex16 16
2,157,790 94 Ex16
2,157,047 98 Ex17 17-18
2,156,344 55 Ex18
2,156,404 99 Ex19 19-20
2,155,768 98 Ex20
2,155,550 75 Ex21 21
2,155,240 83 Ex21
2,154,725 82 Ex22 22
2,154,431 68 Ex22
2,154,024 128 Ex23 23
2,153,512 Within an exon
2,153,651 Within an exon 23
2,153,183 84 Ex23
2,153,064 93 Ex24 24
2,152,721 94 Ex24
2,152,702 68 Ex25 25-26
2,151,964 98 Ex26
2,150,644 77 Ex27 27-28
2,150,094 73 Ex28
2,150,142 70 Ex29 29-30
2,149,542 103 Ex30
2,148,079 94 Ex31 31-32
2,147,642 87 Ex32
2,147,595 91 Ex33 33-34
2,147,034 115 Ex34
2,144,309 98 Ex35 35-36
2,143,714 98 Ex36
2,143,832 93 Ex37 37
2,143,439 106 Ex37
2,143,190 96 Ex38 38
2,142,856 99 Ex38
2,142,698 105 Ex39 39
2,142,385 96 Ex39
2,142,289 100 Ex40 40-41
2,141,678 104 Ex41
2,141,678 80 Ex42 42
2,141,338 86 Ex42
2,141,213 38 Ex43 43-44
2,140,578 97 Ex44
2,140,687 96 Ex45 45
2,140,180 106 Ex45
2,140,264 69 Ex46 46
2,139,635 Within 3=UTR
eference sequence (GRCh37/hg19).3=
3=
=
3=
3=
3=
3=
=
3=
=however, these procedures do not eliminate the need for
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and to avoid the use of a nested PCR, we have devel-
oped a new method for PKD1 genetic testing by directly
sequencing LR PCR fragments covering the entire PKD1
gene. In this study, the accuracy of the new assay was
evaluated using a panel of DNA samples that were pre-
viously analyzed by two different methods that have been
previously validated.12
Materials and Methods
Study Subjects
Study subjects were participants in The Rogosin Institute
ADPKD Data Repository (NIH clinicaltrials.gov website;
http://clinicaltrials.gov identifier: NCT00792155, last ac-
cessed May 15, 2012). This is a single-center longitudinal
study of genotype and phenotype characteristics of indi-
viduals with ADPKD. Study samples were obtained from
five subjects from the repository who were randomly se-
lected for analysis. All subjects underwent PKD genotyp-
ing by the Athena Diagnostics, Inc., reference laboratory
(Worcester, MA) and by the Weill Cornell Medical Center
Molecular Pathology Research Laboratory, New York,
NY, using direct sequencing and SURVEYOR nuclease–
WAVE screening, respectively. The study was approved
by the Institutional Review Board Committees at Weill
Cornell Medical Center (New York, NY) and The Rocke-
feller University (New York, NY). All subjects provided
written informed consent.
PCR Amplification and Sequencing
Genomic DNA was extracted from peripheral blood lym-
phocytes using standard DNA extraction methods. The
entire coding region, 5= and 3= untranslated regions, and
exon-intron boundaries of PKD1 were amplified in nine
distinct LR PCRs (Gene1, Gene2-7, Gene8-12, Gene13-
15, Gene15-21, Gene22-26, Gene27-34, Gene35-41, and
Gene42-46), using PCR primers (Sigma-Genosys Ltd, St
Louis, MO) anchored in either the rare mismatched re-gion with the HGs or the single-copy region of PKD1. The
LR PCR primer sequences are shown in Table 1. LR PCR
was performed using the GeneAmp High Fidelity PCR
System (Applied Biosystems, Foster City, CA), as previ-
ously described.12 Briefly, 60 ng of genomic DNA was
amplified in a final volume of 25 L, containing 200 mol/L
deoxyribonucleotide triphosphate, 0.2 mol/L of each
primer, 0.5 mol/L betaine, 5% dimethyl sulfoxide (except for
exon 1 with an extremely high content of GC, for which 10%
dimethyl sulfoxide was used), manufacture’s supplied buf-
fer, and 2 U of enzyme. The LR PCR products were ampli-
fied separately using the Biometra T-3000 thermalcycler
(Biometra GmbH, Goettingen, Germany), as described in
Table 2. The LR PCR products of PKD1 were then pu-
rified with the Qiaquick PCR purification kit (Qiagen
Inc., Germantown, MA), quantified, and sequenced
with 45 pairs of walking primers located at least 50 bp
away from intron-exon junctions, using Big Dye Termi-
nator Chemistry with AmpliTaq-FS DNA Polymerase
(Applied Biosystems, Carlsbad, CA) on an ABI 3100
Genetic Analyzer (Table 3). Sequencing data (ABI file)
were analyzed by Mutation Surveyor software version
4.0 (SoftGenetics, State College, PA) for automatic
variation calling first, followed by careful inspection of
the electropherograms for quality assurance purposes.
Assay Analytical Characteristics
An evaluation of the assay analytical characteristics
was performed using only variants located in regions
sequenced by all three methods used and compared
herein, specifically exons and nearby intron se-
quences. The new assay was assessed for sensitivity,
specificity, and accuracy using the following formulas:
sensitivity  number of true positive/(number of true
positive  number of false negative), specificity 
number of true negative/(number of true negative 
number of false positive), and accuracy  (number
of true positive  number of true negative)/(number of
true positive  number of false positive  number of
false negative  number of true negative). The 95%
Figure 1. Top: Map of the PKD1 gene showing
the position of the nine pairs of primers used for
LR PCR amplification of the entire gene. The
structure of the PKD1 gene is shown, with genes
1 to 46 indicated. Black line indicates the dupli-
cated region of PKD1. Bottom: An example of
LR PCR amplification of the DNA fragments (2 to
6 kb long) containing all exons and flanking
regions of PKD1 analyzed on a 0.5% agarose gel
with ethidium-bromide staining. M, size marker.
ions. Th
ns PKD
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the VassarStats statistical application (http://faculty.
vassar.edu/lowry/clin1.html, last accessed May 5th,
2012).
Figure 2. Titration of the amount of input LR PCR DNA in sequencing react
of exon11 (fragment Gene8–12) is shown. There are two variants in the regio
heterozygous mutation in PKD1.Figure 3. A typical electropherogram of Sanger sequencing using 400 ng of LR PCR produc
c.9195 GC (p. ), c.9196 TC (p.F3066L), and c.9330 TC (p. )] in the region could beReference Sequences and Variant Nomenclature
National Center for Biotechnology Information RefSeq se-
quences were used for reference sequence PKD1:
e input DNA varied from 49 to 490 ng. An example of an electropherogram
1 c.2700 GA (p. ) and PKD1 c.2730 CT (p. ). Dashed boxes indicatet. There is a clean backgroundwith low signal to noise, and the three variants [PKD1
easily called. Dashed circles indicate heterozygous mutation in PKD1.
310 Tan et al
JMD July 2012, Vol. 14, No. 4NM_001009944.2. The standard nomenclature recom-
mended by the Human Genome Variation Society (http://
www.hgvs.org/mutnomen, last accessed January 15,
2012)13 was used to number nucleotides and name mu-
Table 4. SummaryofHeterozygousPKD1GeneVariationsbyMethod
Method
SURVEYOR-
WAVE
Direct
sequencing*
LR PCR
sequencing
Missense 14 13 14
Silent 20 17 20
Intronic 8 2 19
Total 42 32 53
*Reference laboratory.
Table 5. Detailed Genotyping Analysis Results for PKD1 by Met
Variants
Exon or
intron Nucleotide change
Amino acid
change Type db
Exon 9 c.1781TA p.F594Y M
Intron 9 c.1850-4AG I rs35
Exon 11A c.2216AG p.Q739R M rs40
Exon 13 c.3063TC p.  S rs23
Exon 14 c.3275TC p.M1092T M rs25
Exon 15A c.3372CT p.  S
Exon 15A c.3375CT p.  S
Exon 15C c.4195TC p.W1399R M
Exon 15D c.4546GA p.A1516T M
Exon 15D c.4665AC p.  S rs71
Exon 15D c.4674GA p.  S
Exon 15E c.5172CT p.  S rs99
Exon 15F c.5611GA p.A1871T M
Exon 15G c.5855GA p.G1952D M
Exon 15I c.6598CT p.R2200C M
Exon 17 c.7165TC p.  S rs24
Exon 18 c.7265CA p.T2422K M
Exon 18 c.7441CT p.  S rs20
Exon 20 c.7708TC p.  S rs28
Exon 21 c.7913AG p.H2638R M rs99
Exon 24 c.8916CT p.  S
Intron 24 c.8949-17AG I rs99
Exon 25 c.8964GA p.  S
Exon 25 c.9195GC p.  S rs99
Exon 25 c.9196TC p.F3066L M rs99
Exon 26 c.9330TC p.  S
Exon 35 c.10535CT p.A3512V M rs34
Intron 38 c.11017-5GT I
Exon 44 c.12133AG p.I4045V M rs10
Exon 45 c.12176CT p.A4059V M rs32
Exon 45 c.12276AG p.  S rs30
Exon 45 c.12409CT p.  S
Exon 46A c.12630TC p.  S rs72
Exon 5B 1119CT p.  S
Intron 10 c.2097  56CT I
Intron 11 c.2854-286CG I
Intron 11 c.2854-269TC I
Intron 15 c.6915  77AT I
Intron 20 c.7863  47TG I rs28
Intron 21 c.8016  26TC I rs99
Intron 22 c.8161  21TC I rs47
Intron 22 c.8161  38GA I rs57
Intron 22 c.8161  269CT I
Intron 22 c.8161  201_8161 
220del
I
Intron 22 c.8161  288_8161 
297del
I
Intron 22 c.8162-262_8162-
263_insCT
I
Intron 23 c.8792-146AG I
Intron 39 c.11269  128CT I rs12
Only variants tested by all three methods (SR-WAVE Seq, Direct Seq,
LR PCR sequencing assay.dbSNP, single nucleotide polymorphism database; I, intonic change; M, m
SURVEYOR-WAVE; X, heterozygous change; H, homozygous change; blank celtations or variants. Sequences were analyzed compared
with the PKD1 gene sequence (accession number:
NG_008617.1) and HGs (accession numbers: NG_00
2797.3, NG_002795.4, NG_002796.4, NG_002800.3,
NG_002798.3, and NG_002799.3). All sequence variant
descriptions were checked for accuracy using the Muta-
lyzer 2.0 program (Mutalyzer website; http://www.mutalyzer.
nl/2.0, last accessed January 15, 2012).
Results
To improve PKD1 testing and to eliminate the need for
nested PCR of the duplicated 5= region, we used an LR
PCR strategy to specifically amplify and directly se-
Patients
KS9 LD9
.
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Seq
Direct
Seq
LR PCR
Seq
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Seq
Direct
Seq
LR PCR
Seq
9 X X X
X X X
X X X
X X X
X X X
X X X
X X X
4 X X X
X X X
X X X
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X X X
X X X
X X X
X X X
X X X
X X X
X X X
9 X X X
X X X
X X X
X X X
X X X
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X, H X, H
X
X
2 X X
X X
X X
2 X X X
X, H
X
X
3 X, H
table continues
PCR Seq) were used to calculate the analytical characteristics of the newhod
SNP no
92965
433
69068
49677
38573
35526
57533
03782
57576
36785
28278
35834
25969
19776
960
09986
87632
03729
61009
34488
86209
92277
91880
and LRissense change; S, synonymous change; Seq, sequencing; SR-WAVE,
l indicates reference allele.
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JMD July 2012, Vol. 14, No. 4quence the entire coding region of the gene. By using
computational analysis, we designed a set of nine oligo-
nucleotide primer pairs that matched the single-copy
gene and rare sequence differences between PKD1 and
the HGs (as described in Materials and Methods). The
relative primer locations and sizes of those fragments are
shown in Figure 1. Agarose gel electrophoresis with
ethidium bromide staining of the LR PCR products dem-
onstrated specific fragments ranging from 2 to 6 kb, each
covering four to seven exons corresponding to the single-
copy sequences of PKD1 (Figure 1). The amount of PCR
product required for sequencing will vary and is mostly
dependent on the size of the fragment. Careful titration of
Table 5. Continued
WA9
SR-WAVE
Seq
Direct
Seq
LR PCR
Seq
SR-WAVE
Seq
X
X X
X X X
X X X
X X
X, H
X
Xinput DNA demonstrated that at least 300 ng of DNA was
required for optimal detection of sequence variations.
Figure 2 demonstrates an example of the titration results
for the Gene8-12 LR PCR fragment (4 kb) and the two
DNA changes identified in this fragment. We chose to use
400 ng of PCR product for sequencing of all LR PCR
fragments, which generated high-quality sequencing re-
actions with high-quality reads of up to 1 kb (Figure 3).
To validate the assay, we selected five unrelated pa-
tients with ADPKD who were genotyped by both the ref-
erence laboratory and the Cornell Laboratory using direct
sequencing and the SURVEYOR-WAVE screening
method, respectively. By using the LR PCR sequencing
MM9
t LR PCR
Seq
SR-WAVE
Seq
Direct
Seq
LR PCR
Seq
X
X X X
X X X
X X X
X
X, H X X
X
X
X, H X X
X
XCM9
Direc
Seq
X
97.1%
4% (96.7
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(34 exonic and 19 intronic), including all 32 genetic vari-
ations reported by the reference laboratory and 41 of 42
variations detected by the SURVEYOR-WAVE sequenc-
ing method, indicating that the LR PCR sequencing
method has diagnostic performance that is comparable to
the screening and direct sequencing methods (Table 4). In
addition, this new mutation screening strategy identified
12 intronic changes that were not detectable by the other
two methods, as a result of higher intronic coverage. A
detailed list of all PKD1 genetic variations identified in this
study is shown in Table 5.
An evaluation of the assay analytical characteristics,
using only variants analyzed by all three assays, demon-
strated good agreement among the different methods
(Table 6). When compared with the standard sequencing
method used by the reference laboratory, the LR PCR
sequencing assay had a sensitivity of 100% (95% CI,
86.7% to 100%), a specificity of 98.5% (95% CI, 94.2% to
99.7%), and an accuracy of 98.8% (95% CI, 95.7% to
99.9%); compared with the SURVEYOR-WAVE sequenc-
ing method, the new assay had a sensitivity of 97.1%
(95% CI, 83.4% to 99.9%), a specificity of 100% (95% CI,
96.4% to 100%), and an accuracy of 99.4% (95% CI,
96.7% to 100%) (Table 6).
Discussion
Pseudogene amplification is a particular problem in the
molecular diagnosis of ADPKD. Herein, we describe a
new PKD1mutation screening strategy based on LR PCR
amplification of the entire gene, using nine pairs of care-
fully designed PCR primers. By using this strategy, we
have correctly identified, in five randomly selected pa-
tients with ADPKD, all gene variations previously identi-
fied by the reference laboratory and all except one iden-
tified by the SURVEYOR-WAVE screening method
described earlier by our laboratory.12 In addition, this
method expands the test coverage to include deep in-
tronic regions, increasing the overall detection rate of
genetic variations by 39.6% (from a total of 32 to 53
variants) compared with the reference laboratory.
Humans possess at least six PKD1 homologues rang-
ing from 18.1 to 29.5 kb, encompassing 33 exons on
Table 6. Sensitivity and Specificity of the LR PCR Sequencing Me
LR PCR versus direct sequencing
LR PCR
sequencing
Direct sequencing
Variants
(positive)
Reference alleles
(negative) Tot
Variants (positive) 32 2 3
Reference alleles
(negative)
0 131 13
Total 32 133 16
Compared with the direct sequencing assay (reference laboratory):
CI)  131/(131  2)  98.5% (94.2% to 99.7%), and accuracy (95%
with the SURVEYOR-WAVE assay: sensitivity (95% CI)  34/(34  1) 
to 100%), and accuracy (95% CI)  (34  130)/(34  1  130  0)  99.chromosome 16, significantly complicating genetic anal-ysis and interpretation of genetic variations.10,14 Re-
cently, we and other laboratories have developed robust
LR PCR strategies, using genomic DNA, to enable muta-
tion screening of the reiterated regions of PKD1. Similarly,
the new strategy described herein broadens the use of
this method to the entire gene, including the single-copy
regions of PKD1 (exons 34 to 46), circumventing the need
for enzyme digestion of PCR fragments or calibration of
PCRs for each of the individual exons. Overall, our
method identified all variations reported by the reference
laboratory and 97.6% (41/42) of the genetic variations
detected by the SURVEYOR-WAVE method, detecting an
additional 12 intronic changes that were not detected by
the other two methods. We also confirmed that the se-
quence of these fragments corresponds to a unique se-
quence, which is PKD1 and not one of its six homologues.
Direct sequencing is considered the method of choice
for mutation detection in many laboratories because
screening methods may not detect all sequence or ho-
mozygous variations; however, this method requires mul-
tiple PCRs and is time-consuming and expensive, limiting
the number and size of amplicons primarily to coding
regions. In addition, because of variable efficiencies in
amplification reactions of target regions, setting up the
multiple reactions usually requires intensive optimization,
with special attention to GC-rich areas.
A major advantage of the LR PCR method is the elim-
ination of nested PCR for the first 33 exons of the PKD1-
duplicated region. In our laboratory, this procedure re-
quired 1/105 dilutions of the LR PCR fragments, which
were then used as templates for the second round of
nested PCRs.11,12 This process was especially suscep-
tible to PCR amplification carryover contamination, po-
tentially leading to false-positive results. Consequently,
special precautions were needed, including the use of a
second PCR setup chamber and liquid handler. In addi-
tion, this method has substantially reduced (by 80%)
the number of PCRs. Consequently, the test cost was
lower (approximately $1200) and the time to result was
significantly less (2 weeks) compared with both the
direct sequencing and the SURVEYOR-WAVE screen-
ing methods.
PKD1 is highly polymorphic, with an average of 10 vari-
ants per individual. Reducing the number of PCRs can
LR PCR versus SURVEYOR-WAVE sequencing
LR PCR
sequencing
SURVEYOR-WAVE sequencing
Variants
(positive)
Reference alleles
(negative) Total
ariants (positive) 34 0 34
eference alleles
(negative)
1 130 131
otal 35 130 165
vity (95% CI)  32/(32  0)  100% (86.7% to100%), specificity (95%
2  131)/(32  0  131  2)  98.8% (95.7% to 99.9%). Compared
(83.4% to 99.9%), specificity (95% CI)  130/(130  0)  100% (96.4%
% to 100.0%).thod
al
4 V
1 R
5 T
sensiti
CI)  (3reduce the chance for allele dropout during PCR amplifica-
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JMD July 2012, Vol. 14, No. 4tion, which occurs when a single-nucleotide polymorphism
is located in the primer-binding region of an allele.15
This new strategy has several other demonstrable ben-
efits over standard sequencing and screening methods.
First, it can detect larger genomic rearrangements involv-
ing more than one exon that would be missed by ampli-
fication of individuals exons. Second, it is suitable for
detecting intronic variations important for splicing that
may be located as far as 125 nucleotides away from the
junctions16 and are not detected by the standard meth-
ods that primarily target the intron-exon junctions of the
gene. On average, the LR PCR–based sequencing
method covers at least 200 to 300 bp of intronic se-
quences away from the exon-intron junction. By contrast,
the direct sequencing and screening methods used are
substantially limited in coverage of intronic sequences to
usually not 10 to 50 bp from the exon-intron junction.
This is important because intronic changes can induce
aberrant splicing by generating alternative splice sites or
destroying the branch site; therefore, better coverage of
these regions would increase the mutation detection
rate.17–19 Last, it has the ability to detect homozygous
changes that are only detected with direct sequencing, but
not with other screening methods, such as SURVEYOR-
WAVE or denaturing high-performance liquid chromatogra-
phy, thus significantly improving the overall detection rate of
genetic variations.12,20 Finally, LR PCR methods play an
important role in sequencing of repetitive or duplicated re-
gions by next-generation sequencing applications, which
cannot be analyzed by the standard genomic amplification
or exome enrichment procedures.21
The primary limitation of this method is that DNA sam-
ples that are partially degraded, such as DNA extracted
from paraffin-embedded tissue, can be more difficult to
amplify. However, peripheral blood lymphocyte DNA and
buccal cell DNA, routinely used for genetic tests, gener-
ally work well.22,23 Another limitation of LR PCR is the
requirement for computational evaluation of the dupli-
cated DNA regions and careful primer design to ensure
amplification of the single-copy sequences.
In conclusion, the LR PCR sequencing method has sev-
eral advantages for the detection of PKD gene variants,
including high sensitivity, improved intronic coverage, faster
turnaround time, and lower cost, providing a reliable tool of
genetic analysis of complex genes and repetitive se-
quences. The LR PCR–based strategy can be applied to
other genes in which variants have escaped detection, re-
gardless of whether pseudogenes are present.
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